Skip to navigation Skip to content
  • Woodruff
  • Business
  • Health Sciences
  • Law
  • MARBL
  • Oxford College
  • Theology
  • Schools
    • Undergraduate

      • Emory College
      • Oxford College
      • Business School
      • School of Nursing

      Community

      • Emory College
      • Oxford College
      • Business School
      • School of Nursing
    • Graduate

      • Business School
      • Graduate School
      • School of Law
      • School of Medicine
      • School of Nursing
      • School of Public Health
      • School of Theology
  • Libraries
    • Libraries

      • Robert W. Woodruff
      • Business
      • Chemistry
      • Health Sciences
      • Law
      • MARBL
      • Music & Media
      • Oxford College
      • Theology
    • Library Tools

      • Course Reserves
      • Databases
      • Digital Scholarship (ECDS)
      • discoverE
      • eJournals
      • Electronic Dissertations
      • EmoryFindingAids
      • EUCLID
      • ILLiad
      • OpenEmory
      • Research Guides
  • Resources
    • Resources

      • Administrative Offices
      • Emory Healthcare
      • Academic Calendars
      • Bookstore
      • Campus Maps
      • Shuttles and Parking
      • Athletics: Emory Eagles
      • Arts at Emory
      • Michael C. Carlos Museum
      • Emory News Center
      • Emory Report
    • Resources

      • Emergency Contacts
      • Information Technology (IT)
      • Outlook Web Access
      • Office 365
      • Blackboard
      • OPUS
      • PeopleSoft Financials: Compass
      • Careers
      • Human Resources
      • Emory Alumni Association
  • Browse
    • Works by Author
    • Works by Journal
    • Works by Subject
    • Works by Dept
    • Faculty by Dept
  • For Authors
    • How to Submit
    • Deposit Advice
    • Author Rights
    • Publishing Your Data
    • FAQ
    • Emory Open Access Policy
    • Open Access Fund
  • About OpenEmory
    • About OpenEmory
    • About Us
    • Citing Articles
    • Contact Us
    • Privacy Policy
    • Terms of Use
 
Contact Us

Filter Results:

Author

  • Agius, Mark (1)
  • Ashokkumar, Akshata (1)
  • Bashir, Khurram (1)
  • Bermel, Robert (1)
  • Coffey, Christopher S. (1)
  • Cohen, Bruce (1)
  • Conwit, Robin (1)
  • Coyle , Patricia (1)
  • Cudkowicz, Merit E. (1)
  • Delgado, Silvia (1)
  • Dewitt, Dana (1)
  • Ecklund, Dixie (1)
  • Fox, Robert J. (1)
  • Giesser, Barbara (1)
  • Gleason, Trevis (1)
  • Goldman, Myla (1)
  • Goodman, Andrew (1)
  • Jubelt, Burk (1)
  • Klawiter, Eric C. (1)
  • Koepp, Maxine (1)
  • Lava, Neil (1)
  • Long, Jeffrey (1)
  • Lynch, Sharon (1)
  • Matsuda, Kazuko (1)
  • McGovern, Michelle (1)
  • Miravalle, Augusto (1)
  • Moses, Harold (1)
  • Naismith, Robert (1)
  • Natarajan, Sneha (1)
  • Ontaneda, Daniel (1)
  • Perumal, Jai (1)
  • Racke, Michael (1)
  • Ramachandran, Srividya (1)
  • Repovic, Pavle (1)
  • Riley, Claire (1)
  • Severson, Christopher (1)
  • Shinnar, Shlomo (1)
  • Skaramagas, Thomai (1)
  • Suski, Valerie (1)
  • Thornell, Brenda (1)
  • Weinstock-Gutman, Bianca (1)
  • Yadav, Vijayshree (1)
  • Yankey, Jon (1)
  • Zabeli, Aram (1)

Journal

  • Contemporary Clinical Trials (1)

Keyword

  • allodynia (1)
  • atrophi (1)
  • brain (1)
  • clinic (1)
  • composit (1)
  • disabl (1)
  • experiment (1)
  • function (1)
  • ibudilast (1)
  • imag (1)
  • impair (1)
  • inhibitor (1)
  • lesion (1)
  • life (1)
  • load (1)
  • magnet (1)
  • mechan (1)
  • multipl (1)
  • neuropath (1)
  • neuroprotect (1)
  • pain (1)
  • pharmaci (1)
  • pharmacolog (1)
  • phosphodiesteras (1)
  • progress (1)
  • rat (1)
  • research (1)
  • reson (1)
  • scienc (1)
  • sclerosi (1)
  • technolog (1)
  • trial (1)

Author department

  • Neurology: General (1)

Search Results for all work with filters:

  • 2016
  • Flores, Angela
  • Biology, Neuroscience
  • biomedicin
  • medicin

Work 1 of 1

Sorted by relevance

Article

Design, rationale, and baseline characteristics of the randomized double-blind phase II clinical trial of ibudilast in progressive multiple sclerosis

by Robert J. Fox; Christopher S. Coffey; Merit E. Cudkowicz; Trevis Gleason; Andrew Goodman; Eric C. Klawiter; Kazuko Matsuda; Michelle McGovern; Robin Conwit; Jai Perumal; Michael Racke; Pavle Repovic; Claire Riley; Christopher Severson; Shlomo Shinnar; Valerie Suski; Bianca Weinstock-Gutman; Vijayshree Yadav; Aram Zabeli; Robert Naismith; Akshata Ashokkumar; Robert Bermel; Dixie Ecklund; Maxine Koepp; Jeffrey Long; Sneha Natarajan; Srividya Ramachandran; Thomai Skaramagas; Brenda Thornell; Jon Yankey; Mark Agius; Khurram Bashir; Bruce Cohen; Patricia Coyle ; Silvia Delgado; Dana Dewitt; Angela Flores; Barbara Giesser; Myla Goldman; Burk Jubelt; Neil Lava; Sharon Lynch; Augusto Miravalle; Harold Moses; Daniel Ontaneda

2016

Subjects
  • Biology, Neuroscience
  • File Download
  • View Abstract

Abstract:Close

Background Primary and secondary progressive multiple sclerosis (MS), collectively called progressive multiple sclerosis (PMS), is characterized by gradual progression of disability. The current anti-inflammatory treatments for MS have little or no efficacy in PMS in the absence of obvious active inflammation. Optimal biomarkers for phase II PMS trials is unknown. Ibudilast is an inhibitor of macrophage migration inhibitor factor and phosphodiesterases-4 and − 10 and exhibits possible neuroprotective properties. The goals of SPRINT-MS study are to evaluate the safety and efficacy of ibudilast in PMS and to directly compare several imaging metrics for utility in PMS trials. Methods SPRINT-MS is a randomized, placebo-controlled, phase II trial of ibudilast in patients with PMS. Eligible subjects were randomized 1:1 to receive either ibudilast (100 mg/day) or placebo for 96 weeks. Imaging is conducted every 24 weeks for whole brain atrophy, magnetization transfer ratio, diffusion tensor imaging, cortical brain atrophy, and retinal nerve fiber layer thickness. Clinical outcomes include neurologic disability and patient reported quality of life. Safety assessments include laboratory testing, electrocardiography, and suicidality screening. Results A total of 331 subjects were enrolled, of which 255 were randomized onto active study treatment. Randomized subjects were 53.7% female and mean age 55.7 (SD 7.3) years. The last subject is projected to c omplete the study in May 2017. Conclusion SPRINT-MS is designed to evaluate the safety and efficacy of ibudilast as a treatment for PMS while simultaneously validating five different imaging biomarkers as outcome metrics for use in future phase II proof-of-concept PMS trials.
Site Statistics
  • 16,941
  • Total Works
  • 3,669,290
  • Downloads
  • 1,145,201
  • Downloads This Year
  • 6,807
  • Faculty Profiles

Copyright © 2016 Emory University - All Rights Reserved
540 Asbury Circle, Atlanta, GA 30322-2870
(404) 727-6861
Privacy Policy | Terms & Conditions

v2.2.8-dev

Contact Us Recent and Popular Items
Download now